Home・Akcijų sąrašas・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

104.91 2.15

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

98.73

Max

103.88

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-8.1M -56M
Pardavimai	2.9M 60M
Pelnas, tenkantis vienai akcijai	-0.83
Pelno marža	-92.559
Darbuotojai	414
EBITDA	-7.6M -50M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+34.02% upside

Dividendai
By Acuity
Kitas uždarbis	2026-08-04

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	1.4B 7.3B
Ankstesnė atidarymo kaina	102.76
Ankstesnė uždarymo kaina	104.91

Naujienos nuotaikos

By Acuity

50%

151 / 340 reitingas Healthcare

Rhythm Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-03 19:51; UTC

Rhythm Pharmaceuticals Inc shares are higher today amid unusually high trading volume, continuing the upward trend since Friday's close. No specific news was identified.

2026-07-31 22:56; UTC

Rhythm Pharmaceuticals Inc shares are higher in after-market trading, despite earlier fluctuations and no specific news identified to explain the movement.

2026-07-30 18:46; UTC

Rhythm Pharmaceuticals Inc shares are lower today, continuing a downward trend since Wednesday. No specific news has been identified to explain the decline.

2026-07-29 18:46; UTC

Rhythm Pharmaceuticals Inc shares are lower today, influenced by rising oil prices amid escalating Middle East tensions, though no specific company news was identified.

2026-07-28 19:11; UTC

Rhythm Pharmaceuticals Inc. shares are higher today, supported by strong trading volume and positive momentum in the biotechnology sector. No specific news was identified.

2026-07-27 19:33; UTC

News

RYTM trades higher after JPMorgan's Overweight rating and $145 target.

2026-07-24 21:01; UTC

Rhythm Pharmaceuticals Inc shares are higher in after-market trading, reflecting a positive shift since Friday's close despite broader market challenges.

2026-07-21 14:36; UTC

News

Rhythm Pharmaceuticals will report second-quarter 2026 results on August 4, contributing to higher shares amid positive market sentiment and gains in the Nasdaq 100 Index.

2026-07-20 20:51; UTC

Rhythm Pharmaceuticals Inc is lower in after-market trading, down significantly from Monday's close and below its 20-day moving average. No specific news was identified.

Akcijų palyginimas

Kainos pokytis

Rhythm Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

34.02% į viršų

12 mėnesių prognozė

Vidutinis 137.75 USD 34.02%

Aukščiausias 159 USD

Žemiausias 105 USD

Remiantis 13 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Rhythm Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

13 ratings

Pirkti

Laikyti

Parduoti

Remiantis 13 analitikų, pateikusių Rhythm Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

151 / 340 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.